Ardelyx (ARDX) Short-term Investments (2016 - 2026)
Ardelyx's (ARDX) quarterly Short-term Investments came in at $206.9 million in Q1 2026, up 12.95% YoY from $183.1 million in Q1 2025, and up 5.17% on a QoQ basis from $196.7 million in Q4 2025.
Ardelyx (ARDX) Short-term Investments (2016 - 2026) Analysis & Trends
Ardelyx (ARDX) has 11 years of Short-term Investments data on file, last reported at $206.9 million in Q1 2026.
- Quarterly Short-term Investments rose 12.95% year-over-year to $206.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $206.9 million (up 12.95% YoY) and the FY2025 annual result came in at $196.7 million, up 6.22% from the prior year.
- Short-term Investments climbed to $206.9 million in Q1 2026, from $196.7 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $206.9 million in Q1 2026 to a low of $27.6 million in Q2 2022.
- A 5-year average of $125.3 million and a median of $144.1 million in 2024 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2022 — Short-term Investments plunged 67.55% — and 2023, when it jumped 486.37%.
- Tracing ARDX's Short-term Investments over 5 years: stood at $27.8 million in 2022, then jumped by 486.37% to $162.8 million in 2023, then grew by 13.72% to $185.2 million in 2024, then climbed by 6.22% to $196.7 million in 2025, then grew by 5.17% to $206.9 million in 2026.
- The last three Short-term Investments figures came in at $206.9 million (Q1 2026), $196.7 million (Q4 2025), and $200.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 184.64 Mn |
| Mar 31, 2026 | 206.87 Mn |
| Dec 31, 2025 | 196.69 Mn |
| Sep 30, 2025 | 199.99 Mn |
| Jun 30, 2025 | 148.41 Mn |
| Mar 31, 2025 | 183.14 Mn |
| Dec 31, 2024 | 185.17 Mn |
| Sep 30, 2024 | 142.97 Mn |
| Jun 30, 2024 | 144.07 Mn |
| Mar 31, 2024 | 166.43 Mn |
| Dec 31, 2023 | 162.83 Mn |
| Sep 30, 2023 | 131.31 Mn |
| Jun 30, 2023 | 97.52 Mn |
| Mar 31, 2023 | 37.89 Mn |
| Dec 31, 2022 | 27.77 Mn |
| Sep 30, 2022 | 29.00 Mn |
| Jun 30, 2022 | 27.60 Mn |
| Mar 31, 2022 | 42.63 Mn |
| Dec 31, 2021 | 44.26 Mn |
| Sep 30, 2021 | 66.36 Mn |